Penumbra (NYSE:PEN) received mixed analyst ratings over the last three months, with 6 analysts offering diverse perspectives. The average 12-month price target is $269.00, with a high of $295.00 and a low of $240.00. Recent actions include both raised and lowered price targets and ratings. Penumbra develops medical devices and has shown a revenue growth of 26.8% as of September 30, 2023. However, it has below-average net margin, ROE, and ROA, but a low debt-to-equity ratio of 0.21. The company's market capitalization is below industry averages.